Teva VP Ika Abravanel resigns
Perrigo has already boosted the workforce at its two Negev plants by 40% over the past three years to 900 employees.
Perrigo Company (Nasdaq:PRGO; TASE:PRGO) will invest $40 million over three years to expand its plants in Yeruham and Ramat Hovav in the Negev. Perrigo EVP global operations and supply chain John Hendrickson made the announcement at a press conference in Yeruham today.
Hendrickson said that Perrigo's Israeli operations included both production and R&D, and were part of its core business. He cited the diligence, commitment and education of the plant's employees, and added that government incentives facilitated the company's decision to keep hundreds of employees in the Negev.
Perrigo has boosted the workforce at its two Negev plants by 40% over the past three years to 900 employees, 40% of whom have university degrees. The company has invested $280 million in the plants over the years, as well as $30 million in R&D in Israel.
Perrigo posted $3 billion (NIS 11.4 billion) revenue in 2011. Sales by its Israeli operations totaled NIS 1.6 billion in 2011, up 20% over 2010, and the company expects double-digit growth in 2012. Exports from the two plants exceeded $1 billion in 2011, and they are the company's largest development and production centers outside the US.
The Yeruham plant develops and produces a range of generic drugs, especially complex dermatology products, the original business of Agis Pharmaceuticals, which Perrigo acquired. The Ramat Hovav plant is a leading global developer and producer of active pharmaceutical ingredients (APIs) for the generic drug industry, with more than 300 customers.
Perrigo is 125 years old. It was a private company until it acquired Agis, which was traded on the TASE, for $900 million in 2005. Perrigo took the opportunity to list on Nasdaq, and become dual-listed. The company achieved 10% organic growth in the six years following the Agis acquisition, and 47% growth including acquisitions.
Hendrickson said that Perrigo was very optimistic about its growth in 2012. "Our growth opportunities are excellent in the US, which accounts for 70% of our business, as well as in other countries. We're expanding in the US and Europe, especially in pharmaceuticals, and in the functional food sector elsewhere in the world. The economic crises in the US and Europe actually help us, because they push consumers to use generic treatments," he said.
As for biosimilars, Hendrickson said, "At the moment, we're look with curiosity from the outside, and we have not yet made any substantial investment in the field. Although we won't be pioneers in the field, when it develops, we'll probably enter it quickly."
Perrigo's share price rose 0.8% by mid-afternoon on the TASE today to NIS 445.60, after rising 0.7% on Nasdaq yesterday to $115.50, giving a market cap of $10.8 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on June 21, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.